Company Profile for Urigen Pharmaceuticals, Inc.

• Press Release
• Source: Urigen Pharmaceuticals, Inc.
• On 10:20 am EDT, Friday October 30, 2009

--(BUSINESS WIRE)--About Urigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's two lead programs target significant unmet medical needs and major market opportunities in urology. Urigen's URG101, a proprietary combination of approved drugs that is instilled into the bladder, targets painful bladder syndrome, which affects approximately 10.5 million men and women in North America. Urigen's URG301, a proprietary dosage form of an approved drug that is locally delivered to control urinary urgency, targets acute urgency in females diagnosed with an overactive bladder, another major unmet need that is insufficiently managed by presently available overactive bladder drugs. For further information, please visit Urigen's website at http://www.urigen.com.

Company:		Urigen Pharmaceuticals, Inc.
Headquarters Address:		27 Maiden Lane
		Suite 595
		San Francisco, CA 94109
Main Telephone:		415-781-0350
Ticker:		URGP(OTCBB)
Type of Organization:		Public
Industry:		Pharmaceutical
Key Executives:		CEO: William Garner
		CFO: Martin Shmagin
Investor Relations
Contact:		Martin Shmagin
Phone:		415-781-0350
Email:		marty@urigen.com

Buzz up!